Last reviewed · How we verify
KB001
At a glance
| Generic name | KB001 |
|---|---|
| Also known as | KB001-recombinant human anti-Pa PcrV Fab antibody |
| Sponsor | Humanigen, Inc. |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Study to Evaluate the Effect of KB001-A on Time-to-Need for Antibiotic Treatment (PHASE2)
- Dose Escalation Study of KB001 in Cystic Fibrosis Patients Infected With Pseudomonas Aeruginosa (PHASE1, PHASE2)
- Pilot Trial of KB001 in Mechanically-Ventilated Patients Colonized With Pseudomonas Aeruginosa (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- KB001 CI brief — competitive landscape report
- KB001 updates RSS · CI watch RSS
- Humanigen, Inc. portfolio CI